Business Context and Reporting Period
This Form 8-K is a current report filed by Stellar Biotechnologies, Inc. (not Edesa Biotech, Inc.) on June 15, 2015, covering events occurring on June 12, 2015. The company is incorporated in British Columbia, Canada, with principal executive offices in Port Hueneme, California.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity figures. The report focuses exclusively on a corporate governance event regarding equity compensation.
Material Changes
On June 12, 2015, the Company granted 50,000 stock options to two non-employee directors under its Stock Option Plan. The grant details are as follows:
- Exercise Price: CAD$0.89 per common share.
- Grant Date: June 10, 2015.
- Vesting Period: 18 months from the date of grant.
- Expiration Date: June 10, 2022.
Guidance, Outlook, and Risks
The filing contains no management guidance, financial outlook, risk factors, or discussion of contingencies. It serves solely to disclose the stock option grant in compliance with TSX Venture Exchange requirements.
Investor Verification Checklist
- Verify the total number of outstanding shares to assess the dilution impact of the 50,000 new options.
- Confirm the current market price of the common stock relative to the CAD$0.89 exercise price.
- Review the full text of the attached press release (Exhibit 99.1) for additional terms not summarized in the 8-K.
- Check subsequent filings for any changes to the vesting schedule or expiration terms.